Newsletter | October 27, 2025

10.27.25 -- Developing Cannabinoid And Psychedelic Combination Therapies

FEATURED PODCAST

Cannabinoid And Psychedelic Combinations With Incannex Healthcare's Joel Latham

On this Business Of Biotech episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.

INDUSTRY INSIGHTS

The Evolution Of The Modern Medical Monitor

Learn how to identify, hire, and empower a modern medical monitor to help your next study proceed toward submission more productively, and with greater data integrity, than ever before.

Why Legacy ERP Systems Are Draining Your IT Budget

Review how legacy ERP systems hold businesses back, the opportunities they leave unexplored, and why shifting to the cloud could be the game changer your organization requires.

Designing Successful Cell And Gene Therapy Trials

CGTs are ushering in a new era of therapies that address the root causes of illness. Explore key considerations for designing CGT trials, with a focus on optimizing the likelihood of success from the start.

The Streetlight Effect And What Is Happening On Clinical Trial Finders Today

Why aren’t the eligibility criteria of clinical trials searchable? Examine the shortcomings of existing clinical trial finders, particularly regarding the accessibility of eligibility criteria for patients seeking treatment options.

Enhancing Clinical Trial Flexibility

Discover how customized functional partnerships deliver essential expertise, scale resources efficiently, and secure significant cost savings in clinical trials.

Accelerating IND-Enabling Studies With Automated Bioanalysis Workflows

Reimagined as automation-first, bioanalysis shifts from being an Investigational New Drug (IND) bottleneck to a catalyst for innovation—helping companies move therapies forward with greater confidence.